The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

November 05, 2024

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

October 22, 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

October 18, 2024

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

October 15, 2024

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

October 14, 2024

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

October 14, 2024

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

October 10, 2024

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

October 09, 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

October 08, 2024

Elias Jabbour, MD, discusses the role of bosutinib as a standard treatment for patients with CML that is resistant or intolerant to prior TKI therapy.

September 26, 2024

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

September 25, 2024

Bora Lim, MD, discusses the significance of the FDA approval of adjuvant ribociclib for patients with HR-positive, HER2-negative breast cancer.

September 23, 2024

Chad Tang, MD, discusses the potential role for radiation therapy in advanced renal cell carcinoma.

September 23, 2024

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

September 22, 2024

Tapotoclax showed manageable safety, and it reduced bone marrow blasts and transfusion dependence in MDS after HMAs.

September 18, 2024

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

September 16, 2024

Guillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.

September 13, 2024

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

September 11, 2024

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

September 11, 2024

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

September 09, 2024

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.